tailieunhanh - báo cáo hóa học:" Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia | BioMed Central Health and Quality of Life Outcomes Research Open Access Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia Leslie A Lenert 1 2 Marcia FT Rupnow3 and Christine Elnitsky1 2 4 Address Weterans Administration San Diego Health Care System San Diego California USA 2University of California San Diego California USA 3Janssen Medical Affairs . Titusville NJ USA and 4Health Services Research and Development Service Department of Veteran Affairs Washington DC USA Email Leslie A Lenert - llenert@ Marcia FT Rupnow- mrupnow1@ Christine Elnitsky- Corresponding author Published II September 2005 Received 15 June 2005 .J J A. . A. .__ ÌAAC - .r-7 J_ .IA I IO IX77 7 r - CT Accepted 11 September 2005 Health and Quality of Life Outcomes 2005 3 57 doi 1477-7525-3-57 This article is available from http content 3 1 57 2005 Lenert et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Most tools for estimating utilities use clinical trial data from general health status models such as the 36-Item Short-Form Health Survey SF-36 . A disease-specific model may be more appropriate. The objective of this study was to apply a disease-specific utility mapping function for schizophrenia to data from a large 1-year open-label study of long-acting risperidone and to compare its performance with an SF-36-based utility mapping function. Methods Patients with schizophrenia or schizoaffective disorder by DSM-IV criteria received 25 50 or 75 mg long-acting risperidone every 2 weeks for 12 months. The Positive and Negative Syndrome Scale PANSS and SF-36 were used to assess .

TÀI LIỆU LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.